Home
About
Overview
Sharing Data
ORCID
Help
History (11)
Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens.
Liu, Hsiao-Chuan
Immune responses to central nervous system directed adeno-associated virus gene therapy: Does direct CNS delivery make a difference?
Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma.
The Target's the Thing.
See All 11 Pages
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
The Target's the Thing.
Flotte TR. The Target's the Thing. Hum Gene Ther. 2016 07; 27(7):477.
View in:
PubMed
subject areas
Central Nervous System Diseases
Dependovirus
Genetic Therapy
Humans
authors with profiles
Terence R Flotte MD